利奈唑胺治疗慢性脓胸的疗效和安全性分析

Analysis on effects and safety of Linezolid in the treatment of chronic empyema

目的评价利奈唑胺治疗慢性脓胸的临床疗效及安全性。方法回顾性分析解放军309医院2009年1月-2013年6月收治的慢性脓胸患者，分为利奈唑胺治疗组（38例）和万古霉素治疗组（32例）．比较两纽患者的临床治疗总有效率、细菌清除率及不良反应发生率等指标。结果利奈唑胺组与万古霉素组临床总有效率分别为89．5％、62．5％，差异有显著性（P〈0．05）；细菌清除率分别为78．9％、65．6％，差异无显著性（P〉0．05）：不良反应发生率分别为7．9％、25．0％，差异有显著性（P〈0．05）。结论利奈唑胺组治疗慢性脓胸临床疗效优于万古霉素组，对慢性脓胸患者疗效确切，安全有效。

[Objective] To investigate the effect and safety of Linezolid in the treatment of chronic empyema. [ Methods ] 70 cases with chronic empyema in pnenumology department of the 309th Hospital of Chinese PLA from January 2009 to July 2013 were analyzed by randomized control trial, compared the cure rate, bacterium clearance and adverse-effect incidence rate in Linezolid group （include 38 patients） and Vancomycin group （include 32 patients）. [ Results ] There was significant difference （P 〈0.05） between Linezolid group and Vancomycin group in cure rate （89.5%, 62.5%） and adverse-effect incidence rate （7.9%, 25%）. But there was no significant difference between them on the rate of bacterium clearance （78.9%, 65.6%）. [ Conclusions ] Linezolid is safe and effective in the treatment of chronic empyema.